(Total Views: 602)
Posted On: 11/26/2024 12:11:03 PM
Post# of 148870
It's a great list to be able to go back and review everything that has transpired and what has yet to materialize. There has been tremendous positive developments over the past 12 months and I suspect quite a few more before January 2025..
Two studies that I saw in the September Letter to Shareholders that have not had any updates:
"CytoDyn is pursuing two other clinical studies linked to inflammation. First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy. We are also grateful to the foundation that has tentatively agreed to fund this study but wishes to remain anonymous at this time.
Finally, CytoDyn is also in the process of organizing a pilot study in patients with chronic fatigue syndrome who demonstrate elevated markers of chronic inflammation. Additional information will be provided in future shareholder updates."
Two studies that I saw in the September Letter to Shareholders that have not had any updates:
"CytoDyn is pursuing two other clinical studies linked to inflammation. First, we are working on a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease. The study will evaluate a neuroradiology primary endpoint to determine efficacy. We are also grateful to the foundation that has tentatively agreed to fund this study but wishes to remain anonymous at this time.
Finally, CytoDyn is also in the process of organizing a pilot study in patients with chronic fatigue syndrome who demonstrate elevated markers of chronic inflammation. Additional information will be provided in future shareholder updates."
(14)
(0)Scroll down for more posts ▼
